Tüdőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• EGFR 301
• PD-L1 162
• PD-1 156
• KRAS 97
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• TROP2 14
• CTNNB1 0
• RAS 15
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2031. szept.

• NIH NIEHS · F31

  PhosFate: Investigating Chemical Hazards, Community Exposures, and Health Risks from Phosphate Fertilizer Manufacturing

  University of South Florida· Tampa, Egyesült Államok· 41 102 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, Egyesült Államok· 77 580 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NCI · R01

  Role of Allostatic Load in Immunotherapy Outcomes

  Ut Southwestern Medical Center· Dallas, Egyesült Államok· 389 844 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 401 115 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spanyolország· EU contribution 262 393 EUR· until 2030. febr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Svájc· EU contribution 1 874 590 EUR· until 2032. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 216 240 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 426 534 EUR· until 2030. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 1451 running projects, newest first. Listed amounts together: 841,1 M USD + 224,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Frissítve: 2026. szept. 22.

  “Closed due to slow accrual.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

  NCT02769962· National Cancer Institute (NCI)· Frissítve: 2026. aug. 13.

  “Accrual and drug manufacturing and supply were discontinued in 2025.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

  NCT06130254· M.D. Anderson Cancer Center· Frissítve: 2026. ápr. 9.

  “Sponsor discontinued the trial”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Forrás

• Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  NCT05797168· AstraZeneca· Forrás

• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Forrás

• PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

  NCT04209595· National Cancer Institute (NCI)· Forrás

• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

  NCT02769962· National Cancer Institute (NCI)· Forrás

• A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

  NCT04826341· National Cancer Institute (NCI)· Forrás

• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

  NCT04380636· Merck Sharp & Dohme LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 618
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• PRMT1 blockade reverts resistance to KRAS (G12C) inhibition through modulating ferroptosis signalling.

  Int J Oncol, 2026. nov.

• Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer.

  J Med Chem, 2026. nov.

• Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling.

  J Pharm Pharmacol, 2026. nov.

• BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations.

  Mol Cancer Ther, 2026. nov.

  Xiuning Le

• Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer.

  Cancer Discov, 2026. nov.

• mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment.

  Mol Pharm, 2026. nov.

• Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers.

  Cancer Discov, 2026. nov.

• Jolkinolide B induces apoptosis and G1 arrest in A549 cells via JAK2/STAT3 inhibition.

  Pak J Pharm Sci, 2026. nov.

• The influence of LINC00511 and MDM2/MDM4 in lung carcinoma: Implications for immunological therapeutic strategies.

  Pak J Pharm Sci, 2026. nov.

• Biochanin A Induces Cuproptosis and Inhibits Lung Metastasis in triple-negative Breast Cancer.

  Oncol Res, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.